

Axsome Therapeutics, AXS-12-301										AXSOME <small>THERAPEUTICS</small>								
Participant Number:						Rater Initials:			Date:	D	D	M	M	M	Y	Y	Y	Y
#	#	#	#	#	#	A	B	C										
Site Number:						#	#	#	Visit:									

Clinician Global Impression of Severity (CGI-S) – EDS

Considering your total clinical experience with this particular population, what level of severity is the study participant's **excessive daytime sleepiness (EDS)** at this time?

- 1 – Normal, not at all affected
- 2 – Borderline affected
- 3 – Mildly affected
- 4 – Moderately affected
- 5 – Markedly affected
- 6 – Severely affected
- 7 – Extremely affected